Epsilogen is pioneering the development of immunoglobulin E (IgE) antibodies for cancer treatment, leveraging the unique properties of IgE to target solid tumors effectively. The company's lead product, MOv18 IgE, specifically targets ovarian cancer and is notable for being the first therapeutic IgE antibody to enter clinical trials. This innovative approach capitalizes on IgE's enhanced potency, improved access to tumors, and extended tissue half-life, which were demonstrated in a successful Phase I clinical trial where MOv18 IgE was found to be safe and well-tolerated, showing early signs of clinical activity in patients with folate receptor alpha positive cancers.

In addition to its lead candidate, Epsilogen has developed a proprietary IgEG platform that combines the functionalities of IgE and IgG antibodies. This hybrid approach involves fusing specific domains of IgG to the IgE structure, resulting in IgEG antibodies that exhibit high potency and the ability to activate various immune cells, including basophils, macrophages, and natural killer cells. The IgEGs demonstrate significant advantages, such as enhanced serum half-life and the ability to drive immune responses more effectively than traditional IgG antibodies, making them a promising avenue for future cancer therapies.

United Kingdom

Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life.  The company's lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase I trial to treat ovarian cancer. This is the world's first IgE therapeutic to enter the clinic.

Epsilogen

Company Details